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Abstract
Purpose Intravenous (IVIG) and subcutaneous (SCIG) im-
munoglobulin infusions are widely used for the treatment of
patients with primary immunodeficiency (PID) worldwide.
This prospective, multicenter, open-label, single-arm Phase
III study evaluated the efficacy, tolerability, and safety of
IgPro20 (Hizentra®; L-proline–stabilized 20 % human SCIG)
in adult and pediatric Japanese patients with PID.
Methods Patients received three IVIG infusions at 3–4-week
intervals followed by a dose-equivalent switch to weekly
SCIG infusions. A 12-week wash-in/wash-out period was
followed by a 12-week SCIG efficacy period. The primary
efficacy endpoint was the comparison of total serum IgG
trough levels during the IVIG and SCIG efficacy periods by
calculating the geometric mean ratio (GMR).
Results The GMR of IgG trough levels on SCIG versus IVIG
was 1.09 (2-sided 90 % confidence interval: 1.06–1.13). No
serious bacterial infections were reported. Eleven patients
(52.4 %) had infectious episodes with an overall rate of 2.98
infections/patient/year; 7 patients (33.3 %) missed school/
work/daycare due to infection (3.48 days/patient/year). Six-
teen patients (76.2 %) were treated with antibiotics for an
adverse event (AE; 47.6 %) or prophylaxis (23.8 %), resulting
in 167.42 days/patient/year of antibiotic use. During SCIG
treatment, 24 patients (96.0 %) had 269 AEs (0.461 AEs
per/infusion) including local reactions as the most common
AE (20 patients, 80.0 %). Local tolerability of IgPro20
was assessed as “very good” or “good” after 85.4 % of
SCIG infusions. One patient (4.0%) experienced a serious AE
of moderate severity (bacterial infection) that was considered
unrelated to study medication.
Conclusion IgPro20 was effective and well tolerated in
Japanese patients with PID.
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Introduction
Primary immunodeficiency (PID) includes a range of genetic
disorders that are characterized by an intrinsic defect in the
immune system (B- and T-cell defects, phagocytic disorders,
and complement deficiencies) [1]. PID results in the patient’s
predisposition to recurrent multiple infections despite inten-
sive treatment with antibiotics [2, 3].
Prevalence of PID in Japan was determined in a recent
nationwide survey (N=1,240) to be 2.3 PID patients per
100,000 inhabitants, with minimal variations across the
country regions [4]. These results are comparable with the
prevalence of PID in Taiwan (0.77–2.17) and Singapore
(2.7), but are lower than those in European countries
(e.g., 4.4 in France), the Middle East (11.98), and the
US (83.3) [4, 5].
Most patients with PID have a primary antibody deficiency
(PAD) and require immunoglobulin G (IgG) replacement
therapy with regular administration of IgG to prevent infection
and maintain quality of life [3]. Intravenous immunoglobulin
(IVIG) infusions every 3–4 weeks are the current standard
practice in Japan. However, the likelihood of developing
severe and/or systemic adverse reactions and the difficulties
in obtaining venous access, particularly in children, have
prompted the development of alternative modes of IgG deliv-
ery. Consequently, IgG administration by the subcutaneous
route (SCIG) has been developed and is now available in
Europe and the United States [6, 7]. IVIG and SCIG infusions
are the current treatment modalities of choice for patients with
PAD worldwide [8, 9].
Patients and their doctors select SCIG for better flexibility
and freedom from long visits to clinics for IVIG infusions.
SCIG does not require venous access, which is particularly
welcome in children. Additional medical benefits of SCIG
compared with IVIG include lower rates of systemic adverse
events (AEs) and more even serum IgG levels between the
infusions [6, 7, 10]. The latter ensures better protection against
infections over the full period between the infusions and helps
to alleviate or completely avoid the known “wear-off” effects,
such as decrease of an overall well-being and higher proba-
bility of infection development during the last pre-infusion
week [6, 11].
IgPro20 (Hizentra®; L-proline–stabilized 20 % human
SCIG) is the first and only 20 % SCIG preparation approved
in the US (2010) and Europe (2011) for treatment of
PID. It has been found effective and well tolerated in
two Phase III studies in both adult and pediatric patients
with PID [6, 7, 12–14].
This is the first prospective, multicenter, open-label, single-
arm study of SCIG in the Japanese population. Here we report
the results of efficacy, tolerability, and safety evaluation of
SCIG therapy in Japanese patients with PID after a dose-
equivalent switch from IVIG.
Methods
Patients, Inclusion and Exclusion Criteria
Male and female outpatients 75 years of age or younger with
PID requiring IgG replacement therapy were eligible for the
study. The PID diagnosis was based on the diagnostic criteria
defined by the Pan-American Group for Immunodeficiency
and the European Society for Immunodeficiencies [15]. Only
patients who had received at least three doses of IVIG at regular
3- or 4-week intervals at a stable dose (variations of ±10 %
were allowed) prior to enrollment were eligible. For inclusion
in the SCIG period, the patient’s IgG trough levels between
screening (or first mandatory IVIG infusion) and third manda-
tory IVIG infusion should have remained above or equal to
4 g/L, with at least one measurement above or equal to 5 g/L.
Patients who developed a serious bacterial infection (SBI) at
the time of screening or during the mandatory IVIG treatment
period were to be excluded from the study. Other exclusion
criteria included lymphoid systemmalignancy, hyperprolinemia,
known allergies or severe reactions to immunoglobulins or other
blood products, hypoalbuminemia, protein-losing enteropathies,
proteinuria (total urine protein concentration above 0.2 g/L),
known hemophilia, or thrombocytopenia (platelet count below
or equal to 50×109/L). Oral or parenteral steroids were allowed
at doses less than 0.15 mg of prednisone equivalent/kg/day.
Womenwhowere pregnant, breastfeeding, not using appropriate
contraception, or planning a pregnancy during the course of the
study were also excluded.
This study was conducted in accordance with the Interna-
tional Conference on Harmonisation Good Clinical Practice
guidelines, and the Declaration of Helsinki (2008 version).
The study protocol and all other study documents were
approved by the relevant independent Ethics Committees.
Signed written informed consent (written assent for patients
7 years of age or younger at the time of obtaining the
assent) was obtained from the patients or their parents or
legally acceptable representatives prior to any study-related
activities. This study was registered at ClinicalTrials.gov
(study identifier NCT01199705).
Study Design
This prospective, multicenter, open-label, single-arm Phase III
study was designed to evaluate the efficacy, tolerability, and
safety of IgPro20 in Japanese patients with PID requiring IgG
replacement therapy. The primary objective of the study was
to assess whether total serum IgG trough levels achieved with
preceding IVIG treatment could be sustained upon a dose-
equivalent switch to IgPro20.
The study consisted of a screening period, amandatory IVIG
treatment period with three planned infusions at 3- or 4-week
intervals at the same dose as the one administered prior to the
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study, a 12-week SCIG wash-in/wash-out period, and a 12-
week SCIG efficacy period with weekly infusions followed by
a completion or discontinuation visit (Fig. 1). For all patients, a
viral safety follow-up visit was performed 12–17 weeks after
the last SCIG infusion.
Weekly SCIG infusions were allowed to be done at home,
except for the first 3 to 8 infusions conducted at the study site.
These supervised SCIG infusions were provided to train the
patient or their parent or legally acceptable representative who
performed the rest of home-based SCIG infusions.
IgPro20 was infused at predefined injection sites on the
upper arms, abdomen, thighs, and/or lateral hip recommended
by the investigator. The maximum volume per injection site
was 25 mL. The actual point(s) of injection could be changed,
if needed, with each weekly administration. In case of
injection-related local reactions, it was not recommended to
use a certain injection site until the local reaction from the
previous injection had completely resolved.
To provide a dose-equivalent switch to IgPro20, the initial
weekly dose of IgPro20 during the wash-in/wash-out period
was calculated as the previous IVIG dose divided by the IVIG
dosing interval in weeks. If the IVIG dose had been adjusted
during the mandatory IVIG treatment period, the average of
the three actual doses was used for calculations. The initial
IgPro20 dose could be adjusted, if necessary, based on the IgG
trough levels measured during the wash-in/wash-out period,
to achieve IgG trough levels of no less than 5 g/L.
The allowed IgPro20 maximal infusion rate for all simulta-
neously used injection sites during the wash-in/wash-out period
(Weeks 1–12) was 25 mL/h or lower. A stepwise increase up to
35 mL/h was allowed for the subsequent infusions at the inves-
tigator’s discretion, depending on tolerability by the patient.
The main differences between this and the previous two
Hizentra® licensing studies [6, 7] were the inclusion of a
dedicated IVIG treatment period of 3 months and a
pharmacoeconomics analysis.
Efficacy and Safety Assessments
The primary efficacy endpoint was the geometric mean ratio
(GMR) of total serum IgG trough levels on IgPro20 therapy
versus that achieved during the mandatory IVIG treatment
period. Total serum IgG concentration was measured prior to
each IVIG infusion and prior to the IgPro20 infusions atWeek
1 and every fourth week thereafter. Comparable trough levels
were indicated by a GMR close to 1.
Secondary efficacy endpoints included the annualized rates
of SBI (according to the pre-specified US Food and Drug
Administration [FDA] criteria [16]) and both serious and non-
serious infections during the SCIG efficacy period. Patients
were required to keep patient diaries, from which the investiga-
tors extracted the information necessary to evaluate the number
of days missed from work/school or unable to perform normal
daily activities due to infections and duration of hospitalization
due to infections. Duration of antibiotics use for infection
prophylaxis and treatment was assessed from concomitant
medications documented in the Case Report Form.
Safety endpoints were the number, rate, severity, and relat-
edness of any AEs per infusion and patient, local tolerability of
subcutaneous infusions, and changes in vital signs (diastolic
and systolic blood pressure, heart rate, and body temperature)
before and after infusions at the study site. Local tolerability
was assessed by patients between 24 and 72 h after the end of
infusion and was analyzed descriptively by calculating
Fig. 1 Study design. Patients received three mandatory IVIG infusions at
3- or 4-week intervals (times for 4-week intervals are shown in brackets),
followed by 24 weekly SCIG infusions during the wash-in/wash-out
period (Weeks 1–12) and SCIG efficacy period (Weeks 13–25). There
were two follow-up visits: completion visit (Week 25) and viral safety
follow-up visit 12–17 weeks after completion. The horizontal curve sche-
matically represents the expected fluctuations of serum IgG levels before
(dashed curve) and during the SCIG efficacy period (solid curve)
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frequency distributions of assessment categories (“very good”,
“good”, “fair”, or “poor”).
Changes in blood chemistry (albumin, total bilirubin,
creatinine, total protein, lactate dehydrogenase, blood urea
nitrogen, alanine aminotransferase, aspartate aminotransferase,
and alkaline phosphatase), hematology, and urinalysis and
changes in viral safety markers for human immunodeficiency
virus (HIV-1 and HIV-2), hepatitis C virus (HCV), and hepa-
titis B virus (HBV), as compared with baseline assessments,
were also recorded.
Statistical Methods
Sample size calculation to assess the GMR of total serum IgG
trough levels during IVIG versus SCIG treatment (primary
efficacy endpoint) was based upon an assumed residual stan-
dard deviation (SD) of 10 %. A 2-sided 90 % confidence
interval (CI) was estimated to extend from 0.93 to 1.07 times
the GMR if 15 patients were evaluable for the primary anal-
ysis. To account for discontinuations, a total of 25 patients
were planned for enrollment in the study.
The intention-to-treat (ITT) analysis included data from all
patients treatedwith IgPro20 during the efficacy period. The per-
protocol data set (PPS) included all patients who had received at
least six doses of IVIG at 3- to 4-week intervals (pre-study and
during the IVIG study period) followed by uniform weekly
SCIG infusions until at least Week 16 (Fig. 1), with at least
one documented total serum IgG trough level in the efficacy
period. The safety analysis was based on the “all treated” (AT)
data set comprised of all patients who received at least one IgG
(IVIG or IgPro20) dose during any study period.
To ensure correct assessment of the GMR, the primary
efficacy analysis was based on the PPS, thus excluding pa-
tients with dose deviations of >10 %. The GMR (SCIG
efficacy period versus mandatory IVIG treatment) with a 2-
sided 90 % CI was calculated using mean log-transformed
IgG trough levels averaged by patient and treatment period.
Additionally, descriptive statistics were calculated for all IgG
trough levels by visit and by treatment period. Analyses of
secondary efficacy variables were based on the data set used
for ITT analysis and the PPS.
Analyses of safety endpoints were based on the AT set.




A total of 25 patients were screened and enrolled into the
study at nine sites throughout Japan. One patient discontinued
Fig. 2 Patient disposition. All 25
screened patients were enrolled
into the study and received
mandatory IVIG treatment. One
patient discontinued from the
study during the SCIG wash-in/
wash-out period, leaving 24
patients who completed the study
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from the study during the wash-in/wash-out period due to
relocation, leaving 24 patients who completed the study
(Fig. 2).
Themean (SD) age of the patients was 20.5 (13.5) years; 11
patients were ≤16 years of age. Fifteen patients (62.5 %) were
male (Table I).
The most common PID conditions were X-linked agam-
maglobulinemia (XLA; 12 patients [50 %], including one
well-documented rare female case [17]) and common variable
immunodeficiency (CVID; 10 patients [41.7 %]).
Study Drug Administration
All 25 patients received the intended three IVIG infusions
and at least one dose of IgPro20, of which 24 patients
received the intended 12 infusions during the SCIG wash-in/
wash-out period and another 12 infusions during the efficacy
period.
The mean (SD) of individual median weekly IgPro20
doses during the SCIG efficacy period was 87.8 (35.2)
mg/kg body weight (bw; Table II). The mean (SD) of
the weekly equivalents of individual IVIG doses was
77.3 (30.5) mg/kg bw. An increase from the planned dose by
>10 % at any time during the study was documented in 12
patients (48 %).
The mean (range) of the individual infusion rates was
22.90 mL/h (13–25 mL/h) during the SCIG wash-in/wash-
out period and 25.35 mL/h (12–35 mL/h) during the SCIG
efficacy period. The majority of infusions (74.0 %) during the
SCIG efficacy period were home-based.
Efficacy
Primary Efficacy Endpoint
The primary objective of the study was met, as the
GMR of serum IgG trough levels after dose-equivalent
switch from IVIG to SCIG was close to 1, with the CI
within the accepted equivalence range of 0.80 to 1.25
(1.09 in the PPS [90 % CI: 1.06–1.13]). The mean (SD)
IgG trough levels slightly increased from 6.53 (1.40) g/L in
the IVIG period to 7.15 (1.51) g/L in the SCIG efficacy period
(Fig. 3).
The ITT analysis confirmed these results.
Secondary Efficacy Endpoints
No SBIs were reported at any time during the study.
Rates of infection were maintained at a low level during
the SCIG efficacy period, with 11 patients (52.4 %)
experiencing an infection (annualized rate of 2.98 infections
per patient/year; Table III). Seven patients (33.3 %) missed
a total of 19 days from school/work/kindergarten due to
infection (3.48 days per patient/year). One patient (4.8 %)
was hospitalized during the SCIG efficacy period due to
bacterial infection of moderate severity, for a total of 3 days
(0.55 days of hospitalization per patient/year); for details see
the Safety section.
A total of 16 patients (76.2 %) were treated with antibiotics
on 844 days during the SCIG efficacy period, resulting in an
annualized rate of 167.42 days of antibiotic use per patient/year.
Antibiotics were used for both treatment of an AE (10 patients
[47.6 %]) and for prophylaxis (5 patients [23.8 %]).
Table I Demographic characteristics of patients
Patients ITT PPS
Total number of patients 24 21
Gender, n (%)
Male 15 (62.5) 14 (66.7)
Female 9 (37.5) 7 (33.3)
Age [years], median (range) 17.5 (3–58) 19.0 (3–58)
Age group, n (%)
<2 years 0 0
≥2 to <12 years 7 (29.2) 4 (19.0)
≥12 to <16 years 4 (16.7) 4 (19.0)
≥16 to <65 years 13 (54.2) 13 (61.9)
≥65 years 0 0
Asian, n (%) 24 (100) 21 (100)
Body weight [kg], median (range) 44.8 (13–105) 48.9 (13–105)
BMI [kg/m2], median (range) 18.2 (15–33) 18.2 (15–33)
Type of PID, n (%)
CVID 10 (41.7) 9 (42.9)
XLA 12 (50.0) 11 (52.4)
ARAG 1 (4.2) 0
VHyper IgM syndrome 1 (4.2) 1 (4.8)
ARAGautosomal recessive agammaglobulinemia, BMI body mass index,
CVIDcommon variable immunodeficiency, ITT intention-to-treat, nnum-
ber of patients, PID primary immunodeficiency, PPS per-protocol data
set, XLAX-linked agammaglobulinemia
Table II Weekly IgG doses by treatment period (ITT)
Treatment period IVIGa SCIG wash-in/
wash-out
SCIG efficacy
Total number of infusions 72 288 288
IgG dose, mg/kg bw
Mean (SD) 77.3 (30.5) 82.2 (33.4) 87.8 (35.2)
Median 73.00 72.98 77.82
Range, min–max 21.5–144.3 26.4–177.8 26.7–172.7
aWeekly equivalent dose across both application schedules (every 3
weeks and every 4 weeks) was calculated based on individual infusions
bw body weight, ITT intention-to-treat, IVIG intravenous immunoglobu-
lin, SCIG subcutaneous immunoglobulin, SD standard deviation
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Safety
Overall Adverse Events
In the SCIGwash-in/wash-out and SCIG efficacy periods, 24 of
the 25 patients (96.0 %) had a total of 269 AEs, with an overall
AE rate of 0.461 AEs per infusion. All AEs were of mild or
moderate severity, with only 5 AEs (0.009 AEs per infusion) in
3 patients (12.0 %) being of moderate severity. The most
common AEs were local reactions (80.0 %), followed by infec-
tions, the most common being nasopharyngitis (44.0 %), upper
respiratory tract infection (20.0 %), and gastroenteritis (16 %).
All other AEs each occurred in less than 4 patients (≤12 %).
During the mandatory IVIG treatment period, 22 patients
(88.0 %) experienced 49 AEs (0.653 AEs per IVIG infusion).
Temporally Associated and Related Adverse Events
During SCIG treatment, 21 patients (84.0 %) had a total of
175 AEs that were considered by the investigator at least
possibly related to the study drug (0.300 AEs per infusion)
and 23 patients (92.0 %) experienced 203 AEs that were
temporally associated, i.e., occurred within 72 h after an
SCIG infusion (0.348 AEs per infusion; Table IV). The
majority of the causally-related AEs (91.3 %) and both
causally- and temporally-related AEs (91.7 %) were mild
local reactions.
In the IVIG treatment period, 1 patient (4.0 %) had at least
2 possibly related AEs (malaise and pyrexia; 0.027 AEs
per infusion) and 10 patients (40.0 %) had 12 temporally
associated AEs (0.160 AEs per infusion).
None of the infusions was stopped due to an AE. The
IgPro20 infusion rate was increased at the investigator’s dis-
cretion in 8 patients. None of the AEs reported in these
patients could be associated with the increased infusion rate.
Serious Adverse Events
During the SCIG treatment, one serious AE (SAE) of moder-
ate severity was reported (0.002 SAEs per SCIG infusion) that
Fig. 3 Mean total serum IgG
trough levels (PPS). Mean total
serum IgG trough levels are
shown for the PPS (N=21). The
number of patients with available
IgG levels differed from the
original patient number in the PPS
at Week 20 (N=20; *) and Week
24 (N=18; **). Error bars
represent the standard error
of the mean
Table III Summary of secondary
efficacy endpoints (PPS)
a As per “diary days” based on
analysis of patients’ diaries. SBI
serious bacterial infection; PPS
per-protocol data set




Total number of patients or exposure days (diary daysa) 21 1,840 (1,990)
SBIs 0 0
Infection episodes 11 (52.4) 15 (2.98)
Days with antibiotics for infection prophylaxis 5 (23.8) 422 (83.71)
Days with antibiotics for infection treatment 13 (61.9) 458 (90.85)
Days hospitalized due to infectionsa 1 (4.8) 3 (0.55)
Days missed from work/school or unable to perform normal
activities due to infectionsa
7 (33.3) 19 (3.48)
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was considered by the investigator unrelated to study drug. A
22-year-old male with XLA experienced bacterial infection that
was reported as an SAE because of the necessity of hospitali-
zation. The patient was treated with antibacterials and the infec-
tion resolved after 15 days. This infection was not considered an
SBI, as it did not meet the pre-specified US FDA criteria. No
SAEs were reported during the IVIG treatment period.
There were no deaths or AEs resulting in discontinuation of
treatment in this study.
Local Reactions
Local tolerability of 85.4 % of SCIG infusions was assessed
by the patients as “very good” or “good”. In no case was the
local tolerability assessed as “poor”.
AEs of local reactions occurred in 20 patients (80.0 %),
with an overall rate of 0.277 events per infusion. Almost all
local reactions (97.5 %) were temporally associated with
SCIG infusion. The rate of local reactions decreased over time
from 0.389 events per infusion during the SCIG wash-in/
wash-out period to 0.163 events per infusion during the SCIG
efficacy period. The overall rate of local reactions related to
home-based infusions during the efficacy period was compa-
rable with that related to infusions at investigational site
(0.178 events per infusion versus 0.120 events per infusion,
respectively).
Vital Signs, Laboratory Parameters, and Viral Safety
No consistent or clinically relevant changes in vital signs were
reported in this study.
Median values and ranges of hematology, blood chemistry,
and urinalysis did not show any relevant changes over time.
Viral safety screening for HIV-1, HIV-2, HCV, and HBV
foundnopositive viralmarkers at either baseline or 12–17weeks
following the final SCIG infusion.
Discussion
Primary efficacy analysis of this study demonstrated that
IgPro20 administered by the subcutaneous route in uniform
weekly doses was an effective treatment in both adult and
pediatric Japanese patients with PID. A dose-equivalent
switch to SCIG 20 % was effective in maintaining total serum
IgG trough levels equal to or above those achieved on the
previous IVIG therapy (Fig. 3). The annualized rate of infection
during the SCIG efficacy period (2.98 infections/patient/year)
was in line with that observed in previous studies in Europe and
in the US (2.76–5.18 infections/patient/year), as were the num-
ber of days missed from school/work/daycare and days spent in
hospital [6, 7, 12]. The mean weekly dose of IgPro20 during
the SCIG efficacy period was lower in the Japanese population
than that seen in Europe and, in particular, the US [6, 7],
probably due to the specifics of local treatment practices
including limits on maximum dose allowed per patient.
This is the first prospective study of SCIG to incorporate a
mandatory IVIG treatment period into the trial design,
allowing for a more stringent comparison of SCIG and IVIG
treatments than previous IgPro20 studies. As all patients had
received at least 3 IVIG infusions at a stable dose before
enrolling in the study, their IgG levels were expected to be at
steady state by the end of the mandatory IVIG period. A 12-
week SCIG wash-in/wash-out period ensured that the IVIG
treatment did not affect serum IgG trough levels during the
steady state SCIG efficacy period. SCIG dose adjustments
during the wash-in/wash-out period were allowed, but were
unlikely to affect the outcome of the study, as the minimal
target serum IgG trough level (5.0 g/L) was lower than that
achieved during the IVIG treatment period (6.53 g/L).
The male/female imbalance in the patient demographics
can be explained by a large share of XLA patients in the study
population. Of interest, this subgroup included one well-
documented case of XLA in a female patient [17].
Table IV Most common related AEs during the entire SCIG treatment period (SCIG wash-in/wash-out and SCIG efficacy periods) by preferred term (AT)
Preferred term At least possibly related At least possibly related and temporally associated events (72 h)
Number of patients (%) Number of events
(rate per infusion)
Number of patients (%) Number of events
(rate per infusion)
Total number of patients or infusions 25 584 25 584
Any preferred term 21 (84.0) 175 (0.300) 21 (84.0) 170 (0.291)
Local reactionsa 20 (80.0) 160 (0.274) 20 (80.0) 156 (0.267)
Skin and subcutaneous tissue disorders 2 (8.0) 9 (0.015) 2 (8.0) 9 (0.015)
Gastrointestinal disorders 1 (4.0) 1 (0.002) 1 (4.0) 1 (0.002)
Investigations 1 (4.0) 1 (0.002) 0 (0.0) 0 (0.000)
Vascular disorders 1 (4.0) 1 (0.002) 1 (4.0) 1 (0.002)
a Based on 16 MedDRA preferred terms
AE adverse event, ATall treated data set, SCIG subcutaneous immunoglobulin
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Higher rates of antibiotic use in this study compared with
the same outcome in SCIG studies conducted outside Japan
are likely associated with generally higher administration of
antibiotics in Japan [18–20].
IgPro20 was well tolerated. No SAEs related to its
administration were reported during the study. One SAE
(bacterial infection; etiologic agent not identified) of moderate
severity reported during the SCIG efficacy period occurred
due to accidental infection and was considered unrelated to the
study drug.
The overall incidence of AEs including local reactions
during the SCIG wash-in/wash-out and SCIG efficacy periods
(0.461 AEs per patient/year affecting 96 % of patients) was
comparable with the overall AE rates in other SCIG studies in
Europe and in the US (0.288–0.773 AEs per patient/year
affecting 98–100 % of patients) [6, 7]. Mild or moderate local
reactions (swelling, soreness, redness, and induration) are
generally expected when relatively large volumes of IgG are
infused by the subcutaneous route. The overall rates of local
reactions reported in this study were in line with previous
SCIG studies [6, 7, 11, 12].
Conclusions
Weekly SCIG treatment with Hizentra® was effective in pe-
diatric and adult Japanese patients with PID requiring IgG
replacement therapy. The treatment was well tolerated and
demonstrated a highly favorable risk-benefit profile.
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